Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or monitor diseases. It offers tests for HIV and Syphilis, and Zika virus. The company also develops tests for malaria, Dengue virus, chikungunya virus, Ebola, Lassa, Marburg, leptospirosis, Rickettsia typhi, Burkholderia pseudomallei, and Orientia tsutsugamushi. It sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, or DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. The company has collaboration agreements with Concussion Science Group Division of Perseus Science Group LLC for the development of a POC diagnostic test for traumatic brain injury; international diagnostics company to develop a POC diagnostic test for a specific type of cancer; and AstraZeneca for the development of a POC assay for a novel biomarker, as well as with LumiraDx to develop POC diagnostic tests. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Medford, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone631-924-1135
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$24.01 million
Profitability
Miscellaneous
Employees165
Next Earnings Date3/14/2019 (Estimated)
OptionableNot Optionable
Chembio Diagnostics (NASDAQ:CEMI) Frequently Asked Questions
What is Chembio Diagnostics' stock symbol?
Chembio Diagnostics trades on the NASDAQ under the ticker symbol "CEMI."
How were Chembio Diagnostics' earnings last quarter?
Chembio Diagnostics Inc (NASDAQ:CEMI) posted its earnings results on Thursday, November, 8th. The company reported ($0.16) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.06) by $0.10. The company earned $9.38 million during the quarter. Chembio Diagnostics had a negative net margin of 21.04% and a negative return on equity of 34.10%. View Chembio Diagnostics' Earnings History.
When is Chembio Diagnostics' next earnings date?
What price target have analysts set for CEMI?
3 analysts have issued 12 month target prices for Chembio Diagnostics' shares. Their forecasts range from $9.00 to $14.00. On average, they anticipate Chembio Diagnostics' share price to reach $11.50 in the next year. This suggests a possible upside of 69.1% from the stock's current price. View Analyst Price Targets for Chembio Diagnostics.
What is the consensus analysts' recommendation for Chembio Diagnostics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chembio Diagnostics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Chembio Diagnostics.
Has Chembio Diagnostics been receiving favorable news coverage?
Headlines about CEMI stock have trended somewhat positive this week, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Chembio Diagnostics earned a coverage optimism score of 1.7 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Who are some of Chembio Diagnostics' key competitors?
Some companies that are related to Chembio Diagnostics include Corium International (CORI), ZEALAND PHARMA/S (ZEAL), Odonate Therapeutics (ODT), Beyondspring (BYSI), Theratechnologies (THERF), Obseva (OBSV), Aptorum Group (APM), Insys Therapeutics (INSY), Five Prime Therapeutics (FPRX), Innate Pharma (IPHYF), ZIOPHARM Oncology (ZIOP), OvaScience (OVAS), Cytokinetics (CYTK), Rigel Pharmaceuticals (RIGL) and Progenics Pharmaceuticals (PGNX).
What other stocks do shareholders of Chembio Diagnostics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Chembio Diagnostics investors own include Prospect Capital (PSEC), Calumet Specialty Products Partners, L.P (CLMT), Alkaline Water (WTER), Two Harbors Investment (TWO), Blackrock Capital Investment (BKCC), Viper Energy Partners (VNOM), Summit Midstream Partners (SMLP), Roper Technologies (ROP), Oasis Petroleum (OAS) and Real Goods Solar (RGSE).
Who are Chembio Diagnostics' key executives?
Chembio Diagnostics' management team includes the folowing people:
- Mr. John J. Sperzel III, Pres, CEO & Director (Age 55)
- Mr. Neil A. Goldman, Exec. VP & CFO (Age 51)
- Mr. Javan Esfandiari, Chief Science & Technology Officer and Exec. VP (Age 52)
- Ms. Sharon Klugewicz, Sr. VP and Chief Quality & Regulatory Officer (Age 51)
- Dr. Robert Passas Ph.D., Sr. VP & Chief Commercial Officer (Age 65)
Who are Chembio Diagnostics' major shareholders?
Chembio Diagnostics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Nantahala Capital Management LLC (4.77%), ARS Investment Partners LLC (3.80%), Royce & Associates LP (2.73%), Segall Bryant & Hamill LLC (2.03%), Ingalls & Snyder LLC (1.85%) and Gagnon Securities LLC (1.78%). Company insiders that own Chembio Diagnostics stock include John Gary Potthoff, Neil A Goldman, Norman H Pessin and Robert Passas. View Institutional Ownership Trends for Chembio Diagnostics.
Which institutional investors are selling Chembio Diagnostics stock?
Which institutional investors are buying Chembio Diagnostics stock?
CEMI stock was acquired by a variety of institutional investors in the last quarter, including Nantahala Capital Management LLC, Segall Bryant & Hamill LLC, Royce & Associates LP, Stonepine Capital Management LLC, Wexford Capital LP, Gagnon Advisors LLC, Gagnon Securities LLC and Geode Capital Management LLC. Company insiders that have bought Chembio Diagnostics stock in the last two years include John Gary Potthoff, Neil A Goldman, Norman H Pessin and Robert Passas. View Insider Buying and Selling for Chembio Diagnostics.
How do I buy shares of Chembio Diagnostics?
Shares of CEMI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Chembio Diagnostics' stock price today?
One share of CEMI stock can currently be purchased for approximately $6.80.
How big of a company is Chembio Diagnostics?
Chembio Diagnostics has a market capitalization of $116.89 million and generates $24.01 million in revenue each year. The company earns $-6,370,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. Chembio Diagnostics employs 165 workers across the globe.
What is Chembio Diagnostics' official website?
How can I contact Chembio Diagnostics?
Chembio Diagnostics' mailing address is 3661 HORSEBLOCK ROAD, MEDFORD NY, 11763. The company can be reached via phone at 631-924-1135 or via email at [email protected]
MarketBeat Community Rating for Chembio Diagnostics (NASDAQ CEMI)
MarketBeat's community ratings are surveys of what our community members think about Chembio Diagnostics and other stocks. Vote "Outperform" if you believe CEMI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CEMI will underperform the S&P 500 over the long term. You may vote once every thirty days.
